Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Despite the success with tyrosine kinase inhibitors (TKIs) in most patients with chronic
myelogenous leukemia (CML), some patients still experience resistance or intolerance and …

Background Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

Abstract Purpose of Review Over the past two decades, the introduction of tyrosine kinase
inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four …

Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

Opinion statement Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in
the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most popular …

When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic
myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was …